Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.33 |
| ▸ | SCN2B | O60939 | 3/20 | 0.31 |
| ▸ | SCN1A | P35498 | 3/20 | 0.31 |
| ▸ | SCN1B | Q07699 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPD | P32754 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311426 | 0.92 | CMA1 (0.33) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL2312841 | 0.88 | SCN9A (0.34) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL2313859 | 0.83 | CMA1 (0.34) | HPD | |
| SCHEMBL2313864 | 0.83 | CMA1 (0.34) | HPD | |
| SCHEMBL2308881 | 0.81 | SCN9A (0.36) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL2312688 | 0.79 | CMA1 (0.33) | — | |
| SCHEMBL2311937 | 0.78 | CMA1 (0.33) | — | |
| SCHEMBL2317167 | 0.78 | CMA1 (0.47) | SCN9ASCN5A | |
| SCHEMBL2313567 | 0.77 | CMA1 (0.34) | — | |
| SCHEMBL2313765 | 0.76 | ADORA3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | SCN9A 3937/4885SCN5A 3890/4885SCN2B 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.